Orthobiologics in Non-Surgical Treatment of Knee Osteoarthritis: Risks and Benefits for Your Patients and Practice - Details

About the Program

Course Highlights

At the conclusion of the program, attendees will be able to:

  • Describe the current body of knowledge of evidence-based clinical use of biologics in the non-surgical treatment of osteoarthritis (OA).
  • Educate the orthopaedic community on fundamental information and relevant skillsets for emergent treatment modalities as they relate to OA.
  • Address the risks and benefits of orthobiologic applications.
  • Better understand the methodology of AAOS evidence-based quality improvement and clinical decision-making tools based on participant feedback and discussions.

Course Syllabus

7:00 AM to 8:00 Registration / Coffee, Light Snacks

8:00 AM to 9:15 AM Session I: Symposium Introduction

The Scope of Knee OA: Incidence and Economics
David Jevsevar, MD, MBA, FAAOS

Knee OA: One Diagnosis?
Allan Gibofsky, MD, JD, MACR, FACP, FCLM

Measuring Efficacy of Treatment in the Treatment of Knee Osteoarthritis
John C. Richmond, MD, FAAOS

Pharmaceuticals vs. Biologics
S. Raymond Golish, MD, PhD, MBA, FAAOS

9:15 AM to 10:30 AM - Session II: What is the Evidence of Benefit for Non-Surgical OA Treatments? (Big Picture)

Anti-inflammatory medications: NSAIDs and Corticosteroids (Short and Long Acting)
Christian Lattermann, MD, FAAOS

Hyaluronic Acid
Louis F. McIntyre, MD

Glucosamine/Chondroitin Sulfate
Arun Aneja, MD, PhD, FAAOS

Biologics: Pathway Modulators (Loricivivent), PRP, BMAC and Stem Cells
Christian Lattermann, MD, FAAOS

How Do I Know What to Choose?
Scott Rodeo, MD, FAAOS

10:30 AM to 11:45 AM - Session III: Building Blocks for Use of Non-Surgical OA Treatments

The Use of Ultrasound in Knee OA: Fact and Fiction
Andrew I Spitzer, MD, FAAOS

Pharmacologic Considerations: Adjunct Anesthesia, Safe Frequency of Injections (Allergies, Immune Effects)
Allan Gibofsky, MD, JD, MACR, FACP, FCLM

11:45 AM to 12:30 PM – Lunch Served

12:30 PM to 1:45 PM - Session IV: Regulation of In-Office Non-Surgical OA Treatments

Definition of HCTPs, Including an Introduction to the Controversy of Minimally Manipulated, Homologous Use
Philipp Leucht, MD, PhD, FAAOS

Red Light, Yellow Light, Green Light Paradigm: The AAOS Biologics Dashboard
S. Raymond Golish, MD, PhD, MBA, FAAOS

What is the Threshold of Evidence Required for Companies to Market HA, Chondroitin, Corticosteroids, PRP, BMAC, Stem Cells?
Martha M. Murray, MD, FAAOS

1:45 PM to 3 PM Session V: Risks of In-Office Non-Surgical OA Treatments

Orthobiologic Injections: How to Make it Work in the Office and OR
Kenneth R Zaslav, MD, FAAOS

Injectable Therapies and the Reimbursement Landscape
Austin Stone MD PhD

Does the Use of These Modalities Harm Outcomes of a Future Arthroplasty?
Andrew I. Spitzer, MD, FAAOS

3:00 PM – 4:15 PM - Session VI: Future of Non-Surgical OA Treatments

Future Strategies to Pave the Way for the Next Generation of Biologic Medicine
Jason Dragoo, MD, FAAOS

Review of Ongoing Level I Trials
Shane Shapiro, MD

Planned Level I Trials – How to Get Involved 
Scott Rodeo, MD, FAAOS

FDA Regulatory Changes on the Horizon
S. Raymond Golish, MD, PhD, MBA, FAAOS

AAOS Initiatives in Biologics
Martha M. Murray, MD, FAAOS

4:00 PM - Adjourn

 

Who Should Attend?

This educational opportunity is ideal for practicing clinicians at all levels of expertise, especially those who specialize in sports medicine and the treatment of knee osteoarthritis.